LEUKEMIA, MYELOID, ACUTE

This early-stage study tests a new drug, JNJ-90189892, in about 155 people whose acute myeloid leukemia or myelodysplastic neoplasms have not responded to treatment or have returned. The goal is to find a safe dose and see if the drug works, alone or with other medicines. Partici…

This early-stage study tests a new daily pill, BH-30236, in adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or stopped responding to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink ca…

This trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack leukemia cells. Th…

This study is for people with high-risk acute myeloid leukemia (AML) who have had a stem cell transplant. Researchers want to see if giving two drugs, azacitidine and chidamide, after the transplant can help prevent the leukemia from coming back. The study will also check how saf…

This early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…

This study tests a new treatment called Orca-T for people with acute myeloid leukemia or myelodysplastic syndrome. Orca-T is made from a donor's blood cells and is given after a gentle chemotherapy or radiation preparation. The goal is to see if it helps the body accept the trans…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. About 600 adults aged 18 and older who are newly dia…

This study tests a new two-drug combination for adults with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The drugs, DFP-10917 and venetoclax, are given together to see if they are safe and can shrink or eliminate leukemia cells. About 39 p…

This study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in 30 adults whose acute myeloid leukemia has returned or not responded to standard treatment. The goal is to see if this mix can safely help more patients achieve remission. Participants must …

This study tests an experimental drug, enzomenib, in people with acute leukemia and other blood cancers that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 600 participants will take part in t…

This study explores how genetic differences influence side effects and treatment response in adults with newly diagnosed acute myeloid leukemia (AML) who are starting therapy with azacitidine and venetoclax. Researchers will analyze blood samples from 50 participants to look for …